Peptides for Insulin Sensitivity Research

Insulin sensitivity research examines peptides affecting glucose metabolism and insulin action. MOTS-c is studied for mitochondrial-mediated glucose regulation and metabolic flexibility. GLP-1 agonists are investigated for improved fasting and postprandial glucose. MK-677 is examined for IGF-1/GH effects on insulin-independent glucose uptake. Studies focus on GLUT4 translocation, mitochondrial efficiency, and beta-cell function.

GLP-1 RA research shows robust improvements in HbA1c and fasting glucose across large populations with type 2 diabetes. MOTS-c studies demonstrate improved glucose tolerance and mitochondrial metabolic capacity in metabolic syndrome models. MK-677 research suggests IGF-1-mediated metabolic improvements, though insulin sensitivity–specific data are less prominent.

MOTS-c human metabolic data are limited; most evidence derives from animal models. Long-term sustainable improvements in insulin sensitivity after GLP-1 cessation are uncertain. Mechanistic understanding of peptide-mediated GLUT4 translocation in athletes is poor. Lean, insulin-sensitive populations are underrepresented in insulin peptide research.

GLP-1 agonists are ARTG-approved for type 2 diabetes management. MOTS-c and MK-677 are not approved for metabolic enhancement. Prescription access requires a registered medical condition (diabetes, metabolic syndrome). Research-grade supply is legal for institutional research; personal metabolic optimisation is not a TGA-approved pathway.